Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURTIME: immediate versus deferred nephrectomy with sunitinib in synchronous metastatic renal cell carcinoma
NL-OMON34814Phase 3Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sunitinib in renal cell carcinoma (RCC) and metastatic renal cell carcinoma (mRCC) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Progression-free survival. Started Jul 2010; status: active, not recruiting.
02
Drugs
sunitinib
03
Conditions
renal cell carcinoma (RCC)metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NL-OMON34814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34814.